Company Analysis
Sign in

Tarsus Pharmaceuticals, Inc. (TARS)

Nasdaq: TARS · Biological Products, (No Diagnostic Substances) · Irvine, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade6.3
◀ Past 5.6● Present 7.0▶ Future 6.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tarsus Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
10
10 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 1 in 2024 and 3 in 2023
Applications published
20
6 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Tarsus Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in CA)
0 granted
20 published
Tarsus Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
10 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,502,377Method of eradicating ticks that attach to humans using lotilaner formulationsPharmaceuticalsTarsus Pharmaceuticals, Inc.
Jul 22, 202512,364,685Isoxazoline parasiticide formulationsPharmaceuticalsTarsus Pharmaceuticals, Inc.
Mar 25, 202512,257,263Pharmaceutical compositions for demodex related blepharitis and eyelid crustingPharmaceuticalsTarsus Pharmaceuticals, Inc.
Feb 4, 202512,213,964Isoxazoline parasiticide formulationsPharmaceuticalsTarsus Pharmaceuticals, Inc.
Dec 24, 202412,171,750Isoxazoline parasiticide formulations and methods for treating blepharitisPharmaceuticalsTarsus Pharmaceuticals, Inc.
Sep 12, 202311,752,137Ophthalmic compositions for treating ocular Demodex using lotilaner formulationsPharmaceuticalsTarsus Pharmaceuticals, Inc.
Jul 4, 202311,690,827Methods for treating ocular Demodex using lotilaner formulationsPharmaceuticalsTarsus Pharmaceuticals, Inc.
Jul 4, 202311,690,826Methods for treating demodex blepharitis using lotilaner formulationsPharmaceuticalsTarsus Pharmaceuticals, Inc.
Dec 14, 202111,197,847Isoxazoline parasiticide formulations and methods for treating blepharitisPharmaceuticalsTarsus Pharmaceuticals, Inc.
Nov 17, 202010,835,517Methods for treating ocular demodex using isoxazoline parasiticide formulationsPharmaceuticalsTarsus Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 9, 20252025/0312319ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR USEPharmaceuticalsTarsus Pharmaceuticals, Inc. · patent 12,502,377 granted from it
Oct 9, 20252025/0312318ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISPharmaceuticalsTarsus Pharmaceuticals, Inc.
Oct 9, 20252025/0312317ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISPharmaceuticalsTarsus Pharmaceuticals, Inc.
Jul 3, 20252025/0213602PHARMACEUTICAL COMPOSITIONS FOR DEMODEX RELATED BLEPHARITIS AND EYELID CRUSTINGPharmaceuticalsTarsus Pharmaceuticals, Inc.
Apr 24, 20252025/0127762ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISPharmaceuticalsTarsus Pharmaceuticals, Inc.
Jan 16, 20252025/0017908ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISPharmaceuticalsTarsus Pharmaceuticals, Inc. · patent 12,364,685 granted from it
Sep 28, 20232023/0301971ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISPharmaceuticalsTarsus Pharmaceuticals, Inc. · patent 12,213,964 granted from it
Sep 21, 20232023/0293496ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISPharmaceuticalsTarsus Pharmaceuticals, Inc. · patent 12,171,750 granted from it
Jul 13, 20232023/0218584SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXISPharmaceuticalsTarsus Pharmaceuticals, Inc.
Jun 22, 20232023/0190711METHODS FOR TREATING OCULAR DEMODEX USING SPINOSAD FORMULATIONSPharmaceuticalsTarsus Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 6.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TARS · research, not advice